The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Timing is everything:
Where would Youtube be without broadband?
Where would AirbnB have been without the 2008 property crisis?
Where would Uber be without the financial crash of 2008?
It's not good enough to have a Moat around the technology if nobody wants, or needs it.
A high barrier to entry for now technologies exists unless a global infrastructure footprint already exists (Microtox)
A large global societal problem can be solved, with ability to scale through partnerships. It is not good enough to begin when demand begins, it is necessary to be prepared to satisfy demand well in advance.
Ultimately, right time, right place, right tech, right sales, marketing and distribution channels must be aligned.
Get those right and the market is as large as you can manage to satisfy, or lose because of inability to have everything in place to meet the demand.
@trillsg one of the wonderful aspects of collaboration with both Aptamer Group and Avacta Group is that tests can be carried out on our premises, with access to the target, whether it being the inactive Spike-Protein, or the virus itself. If we find the virus is not being captured properly we can work with the collaboration partners who are quickly able to adapt to our specifications to meet the requirements.
When you have binding agents, applied to third party LFD's and then tested further in an external test facility, like PD, you rely on layers with no access to amend, adapt and adopt changes quickly. So do not read anything into negative tests in any third party facility, as negative test are part and parcel of experimental development and should not be seen as a test not working, merely that the test requires adjustment. There is a lot more to results of any binding agent on any particular variant, than just a positive or negative outcome.
Porton Down does not run a wastewater treatment test facility to test for SARS-CoV-2 or other pathogens in any such real-world environment. However, there are alternatives in the UK which may or may not be used to achieve the results for PD units. Porton Down are not involved in clinical trials of BT, so not sure where that came from. Bear in mind, Labskin now have 9000 square feet of laboratory facilities with full access to category 3 laboratories to work on the virus independently. Just being clear on making sure that everyone realises that we are not waiting for any third party to do testing for us. We do the testing for our clients and get paid well for that.
@trillsg was that not a voice from the burning Bush saying "Go forth and multi-bag"
@StuoftheToon I was selling papers since I was 12 years old in DunLaoghaire, working with Scoop-Johnson and then George Davis walking between ever Lounge/Bar from the Harbour Bar at one eld to Walters at the other end, after school, Saturdays and Sunday morning after Mass.
@Newuncle sleep is roughly 5 hours a night, sometimes less but delegation to an amazing team of experts in DeepVerge Group. Last part... Good genes
@T.Rat yes :-)
As Glebe has said, there is so much going on in DVRG, wrapped up in partnerships, collaborations and cooperation agreements, and what has been delivered should not be overlooked in the last 4 months, let alone 6 months. It is worth checking out the end of Q1 update, which is also before the launch of SkinTrustClub and the MoU with China Resources.
https://www.londonstockexchange.com/news-article/DVRG/updates-on-labskin-modern-water-skin-trust-club/14919873
The share price is not something the company has control over, but it is fair to say that we are in excess of 100% where we were 12 months ago.
I have no doubt the end if this year we will be in a stronger position and expect the year end share price to reflect that.
As for MSYS, I am Chairman of the Board and very proud of what the team in that company is doing in turning that company 180 degrees to achieve the same results that we have done here in DeepVerge.
I can only urge you to do the research and be patient as long term we have never been in a better and stronger position than we are now.
There is plenty of RNS references to China in the last 2 months to allow continuation of Twitter comments to expand on what is already in the public domain and all within AIM Rule 10, 11 and EU MAR Article 17 relating to disclosure and delaying disclosure of inside information
RNS 17th February -- Big ticket (c$50,000 USD) online monitors from the Microtox CTM toxicity range and the Microtrace metal OVA range are being produced across two sites with 40 units scheduled for final assembly at our Shanghai, China, facilities in March.
RNS 17th February -- Phase two of our manufacturing plan is being implemented to increase manufacturing capacity in China in Quarter 2, 2021 to double current capacity by year end
RNS 2nd March -- China is an important market for DeepVerge, and the growing interest received, validates our expertise and the need for our advanced water contamination solutions
RNS 12th March -- China is a rapidly expanding market for DeepVerge, and the recognition of yet another Modern Water Monitoring high-tech water contamination detection unit for an award nomination, back to back with 2019 Microtox® FX, winning the innovation product of the year, shows the growing demand for high-tech environmental water monitoring equipment in China, which has set aside $540 billion[ix] to fight pollution
RNS 31st of March -- 2021 looks to be a promising year for DeepVerge with progress ramping up and particularly strong interest from China for our Microtox products, as well as our new Labskin offerings.
There has been 29 questions submitted for tomorrow's webinar. I have responded to them all and will further elaborate on many questions that were asked. The webinar covered all the Projects Labskin, Skin Trust Club, Modern Water Microtox both the Breath Test and Wastewater.
I believe that many overlooked some of what was in a few of the last handful of RNS. The fact we are working in EU and European :-) countries as well as US and China for Microtox PD. All will be explained as best I can under AIM and EU/UK MAR Rules
It is not the final packaging, purely Alpha testing to ensure processing before we release first major batch in beta testing
I hadn't posted in a while, but to give you reason for the type of packaging. Brexit plays a role and shipping from EU to UK posed a problem as a parcel, so we considered the option of ensuring that it could be posted through a letterbox as the life of a swab is finite. Post works, parcels could be delayed. Also, dealing in many thousands of packs, we insisted that it was sustainable, recyclable and environmentally friendly with minimal waste.
@Paulcon62 The value of a specialist PR company (www.beachhutpr.com) in ther tech sector is that they know the space, they understand the demographics and behavioural science behind a PR campaign. It is not about the personal opinion of a few, but the motivation of the many. The beginning of an PR campaign (and I have been through a few consumer campaigns in my career, is that you have to do many A/B tests and target many platforms. There is already good registration numbers, this just helps build momentum to scale. I am happy with the piece in the paper, as it is the first of a 6 month program. I will look at the output in a review in 3 months time and have more insight in US, Canada, UK and Ireland before we push into EU and China later this year
30 million visitors a month to the Sun newspaper. You can confirm that number by going to www.semrush.com and type in www.thesun.co.uk to get the exact stats. More eye-brow, than high-brow, but PR are doing the job they were paid to do.
@T.Rat the website is www.skintrustclub.com and the info domain was used in a A/B Test some time ago, but was left live
Thanks Paulcon62. As I have said many times, I do read the comments. I am actually fascinated by some comments, just I don't take offense because of a phrase someone said to me at a lunch in Dublin in 2004.
"The pleasure is in the knowledge...." fill in the blank yourself.
Having transformed businesses over the last 25 years, the same themes arise. People who feel they are core to the loss making company, rarely are, just they don't realise it until they are dispensed with. Failure to sell means the original sales model and staff were not worth keeping and old production systems usually need replacement. Ex-staff can be as bitter as ex-divorce partners and can't get over how much they weren't needed and fail to accept an alternative to their system can work.
The people who stay usually are empowered to create the kind of culture that thrives once the old regime is gone.
Actually, I don't need to respond.
However the most recent RNS if anyone has the time to read it.
https://www.londonstockexchange.com/news-article/DVRG/prod-n-orders-worth-5m-for-modern-water-equipment/14867523
@andrewoodum the scanner has built in UV to deactivate any pathogen leaving no haz-med waste issue. Completely sustainable end to end process.
I have read some, not all of the comments and some are simply nonsense.
In particular I will comment on one claim that £65m went into Alltracel as utter rubbish. Alltracel raised £11m in equity and used debt to fund additions. When it was sold for £20.8m the US dollars was £1 = $2 and additional debt of $15m. So the deal is often referred to as $55m and even a cursory search would find the following https://www.irishexaminer.com/business/arid-20046029.html
As for other comments about Microsaic, there is some belief that it is possible to turn a company around with no investment.
MSYS would not have gone into Administration, it would have been liquidated. There was no money. There was no short term viable business model. If it had been liquidated, all the staff would be dismissed with no benefits other than statutory redundancy.
Had it gone into liquidation it would be possible to make an offer for the IP and assets of the company and the losses disappear. There is no tax losses, no people and no value as all the institutional knowledge walk out the door. The loss of the people makes it worthless. These are career scientists, software developers who wrote the software for all the microprocessors in the Microsaic machines, chemists, physicists, bio-physicists, admin and in general all the people who made the company valuable.
It is easy to say that they could be re-hired, but after 25 years of turning companies around, a liquidation means you lose the hearts and minds of the people involved. Why would they stay through the liquidation phase? Who would pay them? As far as they are concerned, nobody cares, so you lose them, for good.
£30m and 19 years of dedicated research and development has gone into Microsaic. People have careers in this company. The only problem was the business model was where it was commercially focused. It reminded me of Labskin when I took over Integumen.
Deepverge is on it’s path of rapid expansion and further evidence of that will be seen shortly, for those who have done research, it is obvious.
Turning a company, like Microsaic, requires investment funding. To acquire Microsaic, as a public company costs roughly £600,000, based on the recent total cost of acquiring Modern Water. Microsaic had no money, therefore where would that come from? Maintaining a company with 15 people is roughly a cost and loss of over £2.4m a year, see their 20190 accounts. Who would fund that?
So in order to save it from liquidation and then turn Microsaic, time and money is required. So 2 years money was raised, with the condition that they follow a business model formula that has been successful over many years.
I read the comments, and sometimes wonder how anyone cannot see what is obvious from a business perspective.
Perhaps that is why institutional investors took most of the placing. That is my last comment.
@Chesh, @ValueRebel, I take it you refer to Mrs. CEO :-)
Here's my opinion, FWIW: Any company who have spent £30m and 19 years perfecting a technology, ahead of it's time, for "Industry 4.0" (worth looking that up) and has miniaturised technology, throwing off massive amounts of data, when added to expertise with A.I. and IoT backgrounds, in "Health-Tech" has just been waiting for the right business model, with an existing sales, marketing and distribution channel. Put them in contact and watch the sparks fly.